Management of Cardiac Amyloidosis with Transdermal Buprenorphine

Introduction to Buprenorphine Use

The American College of Cardiology suggests that transdermal buprenorphine can be used cautiously in patients with cardiac amyloidosis for neuropathic pain, but requires close monitoring of blood pressure and cardiac function due to the risk of hypotension in these patients with restrictive physiology 1, 2.
The American College of Cardiology recommends buprenorphine as a relatively safe analgesic option for patients with cardiac amyloidosis who present with neuropathic pain, a common manifestation especially in ATTR amyloidosis 1, 2.

Buprenorphine has a favorable cardiovascular safety profile with fewer effects on respiratory depression compared to other opioids, making it a suitable option for patients with cardiac amyloidosis 3, 4.
The transdermal formulation of buprenorphine avoids first-pass hepatic metabolism, potentially providing better analgesia compared to sublingual formulations 3, 4.

The American Heart Association advises starting with the lowest available dose of transdermal buprenorphine and titrating gradually up to a maximum of 20 mcg/hour, ensuring proper application and adherence 3, 4.
Close monitoring of blood pressure, heart rate, and signs of cardiac decompensation is essential when using transdermal buprenorphine in patients with cardiac amyloidosis 6, 7.

The American College of Cardiology recommends pregabalin, gabapentin, and duloxetine as first-line treatments for neuropathic pain in patients with cardiac amyloidosis, with dosages adjusted according to renal function and tolerance 1, 2, 5.
If first-line treatments are insufficient, transdermal buprenorphine can be considered as a second-line option, with careful monitoring of blood pressure and cardiac function 3, 4.

The American College of Cardiology warns against combining transdermal buprenorphine with oral morphine or other full opioid agonists without proper transition planning, as this can reduce the analgesic effect of morphine and potentially precipitate withdrawal symptoms 8.
Digoxin, calcium channel blockers, and beta-blockers should be avoided or used with caution in patients with cardiac amyloidosis due to the risk of toxicity, hypotension, and negative inotropic effects 6, 7.

Regular monitoring of blood pressure, both supine and orthostatic, is crucial in patients with cardiac amyloidosis, as well as assessment for signs of cardiac decompensation and renal function 1, 2, 6, 7.
The American Geriatric Society recommends consulting the Beers Criteria to identify potentially inappropriate medications in older adults with cardiac amyloidosis 5, 9.